Stock OXIS INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

OXIS International, Inc. Share Price Other OTC

Equities

US6918294025

Pharmaceuticals

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for OXIS International, Inc.
08:18pm Top Midday Decliners MT
05:35pm GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * - Sales 2025 * - Capitalization 10.77M 897M
Net income 2024 * -17M -1.42B Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.72 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.13%
More Fundamentals * Assessed data

Latest news about OXIS International, Inc.

Top Midday Decliners MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT
Top Premarket Gainers MT
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Hopes Build for -3- DJ
More news

Analyst Recommendations on OXIS International, Inc.

EF Hutton Starts GT Biopharma at Hold With $2 Price Target MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9 MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating MT
More recommendations

Press releases OXIS International, Inc.

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AQ
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results AQ
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS AQ
More press releases

News in other languages on OXIS International, Inc.

Caterpillar deja París, el cacao está menos caliente
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud
More news

Managers and Directors - OXIS International, Inc.

Managers TitleAgeSince
Michael Breen CEO
 Chief Executive Officer 62 13/21/13
Manu Ohri DFI
 Director of Finance/CFO 67 18/22/18
Jeffrey Miller PRN
 Corporate Officer/Principal - 14/22/14
Members of the board TitleAgeSince
Charles Casamento BRD
 Director/Board Member 78 01/23/01
Bruce Wendel BRD
 Director/Board Member 70 11/20/11
Rajesh Shrotriya BRD
 Director/Board Member 79 13/21/13
More insiders

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
25/06/2024 - Annual General Meeting
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 332B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 210B
NOVARTIS AG Stock Novartis AG
+10.63% 209B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW